NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00273546,Induction Chemotherapy Comparing TaxotereÂ® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer,https://clinicaltrials.gov/study/NCT00273546,,COMPLETED,"* 1.To compare overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5FU) or the control treatment (PF: cisplatin plus 5-FU) followed by chemoradiotherapy in patients with locally advanced SCCHN.
* 2.The main secondary endpoint is progression free survival (PFS). The other secondary endpoints are to evaluate and compare improvement of local symptoms; time-to-treatment failure; quality of life; clinical complete response rate (CR and CR/PR); toxicity and to evaluate the relationship of tumor markers and response to therapy.",NO,Cancer,DRUG: XRP6976 (Docetaxel/Taxotere),Overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5-FU) or the control treatment (PF: Cisplatin plus 5-FU) followed by chemoradiotherapy.,The main secondary outcome is progression free survival (PFS).|The other secondary endpoints are improvement of local symptoms;time-to-treatment failure;quality of life;|clinical complete response rate (CR) and overall response rate(PR+CR) after chemotherapy and after locoregional therapy(chemoradiotherapy);|duration of response(CR and CR+PR); toxicity.,,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE3,500,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,EFC6043|RP-56976-V-324,1999-05,2006-02,2006-02,2006-01-09,,2009-04-29,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, 08807, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal|Sanofi-Aventis Administrative Office, Moscow, Russian Federation",
